Why the study?
The prognostic potential of biological age estimates derived from sleep-stage analysis and nocturnal heart rhythm patterns for cardiovascular risk stratification remained to be evaluated.
Does biological age estimation derived from sleep-stage analysis and nocturnal heart rhythm patterns predict mortality and cardiovascular risk in patients undergoing polysomnography?
Does biological age estimation derived from sleep-stage analysis and nocturnal heart rhythm patterns predict mortality and cardiovascular risk in patients undergoing polysomnography?
Deep learning-derived biological age from sleep stages and nocturnal ECG patterns serves as a robust biomarker for cardiovascular risk stratification and mortality prediction.
Sleep-derived biological age may aid CVD risk stratification; leaves open need for prospective validation before clinical adoption.
Background: Understanding the intricate relationship between sleep quality and cardiovascular outcomes opens new avenues for risk stratification in cardiovascular diseases (CVDs). This study aims to evaluate the prognostic potential of biological age estimates derived from sleep-stage analysis and nocturnal heart rhythm patterns. Methods: Using polysomnographic data from 1149 patients, we extract ECG signals and use an unsupervised clustering approach to generate time-series clusters that capture dynamic fluctuations in heart rhythms. A subsequent deep learning model then estimated individual biological ages from these clusters, revealing associations between the predicted age, sleep patterns, and cardiac function. Results: In an independent test set of 736 patients, the predicted biological age was significantly associated with increased mortality (Hazard Ratio [HR] 2.27, p < 0.05) and elevated CVD risk (HR 3.56, p < 0.001), while models based solely on nocturnal heart rhythms yielded HRs of 2.29 (p < 0.05) for all-cause mortality and 3.13 (p < 0.01) for CVD risk. Conclusions: These findings demonstrate that integrating sleep stage and ECG offers a robust biomarker for cardiovascular risk stratification, paving the way for earlier interventions and more personalized healthcare strategies.
No takes yet. Share an insight, caveat, or question.
Manimaran et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: